[{"Assets_0_Q3_USD":236388000.0,"CommonStockSharesOutstanding_0_Q3_shares":62691478.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-97671000.0,"NetIncomeLoss_1_Q3_USD":-40528000.0,"NetIncomeLoss_3_Q3_USD":-118930000.0,"StockholdersEquity_0_Q3_USD":97013000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1461000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":2880000.0,"Ticker":"DVAX","CIK":"1029142","name":"DYNAVAX TECHNOLOGIES CORP","OfficialName":"Dynavax Technologies Corporation Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1279198792.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181106"}]